RVL Pharmaceuticals Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
RVL Pharmaceuticals's earnings have been declining at an average annual rate of -3.4%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 5.6% per year.
Anahtar bilgiler
-3.4%
Kazanç büyüme oranı
17.7%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 6.0% |
| Gelir büyüme oranı | 5.6% |
| Özkaynak getirisi | -418.1% |
| Net Marj | -184.9% |
| Son Kazanç Güncellemesi | 30 Jun 2023 |
Yakın geçmiş performans güncellemeleri
Recent updates
RVL Pharmaceuticals plc (NASDAQ:RVLP) Analysts Just Cut Their EPS Forecasts Substantially
Aug 16
Analysts Just Made A Major Revision To Their RVL Pharmaceuticals plc (NASDAQ:RVLP) Revenue Forecasts
May 13RVL Pharmaceuticals plc (NASDAQ:RVLP) Doing What It Can To Lift Shares
May 12RVL Pharmaceuticals (NASDAQ:RVLP) Is Making Moderate Use Of Debt
Apr 20Is RVL Pharmaceuticals (NASDAQ:RVLP) Using Debt Sensibly?
Jan 05RVL Pharmaceuticals sees Q3 net sales of UPNEEQ for eye treatment about $10M
Oct 18RVL Pharmaceuticals: Chapter 2 - A Developing Quandary
Sep 22RVL Pharma in pact with Revision Skincare to broaden access to products
Aug 30GAAP EPS of -$0.14 beats by $0.07, revenue of $8.45M misses by $0.07M
Aug 11RVL Pharma posts preliminary 42% sales growth for eye treatment
Jul 07RVL Pharmaceuticals (NASDAQ:RVLP) Is Carrying A Fair Bit Of Debt
Jul 04RVL Pharmaceuticals: Chapter 1 Gives A Mixed Picture
Jun 15New Forecasts: Here's What Analysts Think The Future Holds For RVL Pharmaceuticals plc (NASDAQ:RVLP)
Apr 01RVL Pharmaceuticals: A Makeover For An Ugly Duckling
Mar 30Osmotica: A Different Breed Of Cat
Dec 14Osmotica Pharmaceuticals (NASDAQ:OSMT) Takes On Some Risk With Its Use Of Debt
Aug 20Osmotica: Paring Down, Focusing On UPNEEQ
Jul 16Gelir ve Gider Dağılımı
RVL Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 23 | 37 | -68 | 67 | 3 |
| 31 Mar 23 | 37 | -56 | 71 | 4 |
| 31 Dec 22 | 50 | -52 | 79 | 4 |
| 30 Sep 22 | 43 | -53 | 85 | 4 |
| 30 Jun 22 | 35 | -66 | 93 | 5 |
| 31 Mar 22 | 38 | -76 | 91 | 4 |
| 31 Dec 21 | 18 | -83 | 84 | 6 |
| 30 Sep 21 | 16 | -115 | 81 | 9 |
| 30 Jun 21 | 40 | -86 | 74 | 9 |
| 31 Mar 21 | 28 | -82 | 72 | 11 |
| 31 Dec 20 | 28 | -89 | 73 | 13 |
| 30 Sep 20 | 87 | -64 | 75 | 18 |
| 30 Jun 20 | 126 | -178 | 78 | 24 |
| 31 Mar 20 | 183 | -285 | 90 | 27 |
| 31 Dec 19 | 240 | -271 | 93 | 32 |
| 30 Sep 19 | 246 | -351 | 95 | 38 |
| 30 Jun 19 | 247 | -243 | 88 | 40 |
| 31 Mar 19 | 261 | -112 | 79 | 43 |
| 31 Dec 18 | 264 | -110 | 74 | 43 |
| 30 Sep 18 | 274 | -1 | 67 | 53 |
| 30 Jun 18 | 262 | -10 | 63 | 50 |
| 31 Mar 18 | 248 | -31 | 60 | 47 |
| 31 Dec 17 | 246 | -41 | 57 | 42 |
| 31 Dec 16 | 218 | -42 | 63 | 29 |
Kaliteli Kazançlar: RVLP.Q is currently unprofitable.
Büyüyen Kar Marjı: RVLP.Q is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: Insufficient data to determine if RVLP.Q's year-on-year earnings growth rate was positive over the past 5 years.
Büyüme Hızlandırma: Unable to compare RVLP.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: RVLP.Q is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Özkaynak Getirisi
Yüksek ROE: RVLP.Q has a negative Return on Equity (-418.14%), as it is currently unprofitable.